Welcome to our dedicated page for Lemaitre Vasculr news (Ticker: LMAT), a resource for investors and traders seeking the latest updates and insights on Lemaitre Vasculr stock.
LeMaitre Vascular, Inc. (NASDAQ: LMAT) is a provider of vascular devices, implants, and services for the treatment of peripheral vascular disease, with products developed for use by vascular surgeons. This news page aggregates company announcements, earnings releases, and other disclosures so readers can follow how LeMaitre’s vascular device business evolves over time.
In its regular quarterly updates, LeMaitre reports on net sales, gross margin, operating income, earnings per share, and geographic sales across the Americas, EMEA, and Asia Pacific. These releases often highlight which product categories, such as grafts, shunts, and catheters, are driving growth, and may call out specific products like the Artegraft biologic graft used in AV access and peripheral bypass. The company also discusses organic sales growth, adjusted profitability metrics, and the impact of pricing, volume, and manufacturing efficiencies.
Beyond earnings, LeMaitre issues news about dividends, share repurchase authorizations, and participation in healthcare and investor conferences hosted by firms such as Bank of America Securities, Wells Fargo, Morgan Stanley, and others. These events provide additional context on the company’s strategy, international expansion, and regulatory milestones, including launches of products like Artegraft in new markets.
Investors and observers can use this page to review historical press releases, monitor guidance updates, and see how management characterizes risks and opportunities in the peripheral vascular disease market. For ongoing coverage of LMAT news, this feed offers a centralized view of the company’s public communications and financial reporting.
LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced it will release its Q1 2022 financial results on April 28, 2022, post-market. A conference call is scheduled for 5:00 PM ET to discuss the results and company outlook. LeMaitre specializes in devices and services for treating peripheral vascular disease, impacting over 200 million globally. The company develops and markets both disposable and implantable vascular devices targeted at vascular surgeons. Further details can be found at www.lemaitre.com.
LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced that Chief Financial Officer JJ Pellegrino will present at the 21st Annual Needham Virtual Healthcare Conference on April 14, 2022, at 10:15 AM ET. LeMaitre specializes in devices and services for treating peripheral vascular disease, impacting over 200 million globally. The company focuses on developing disposable and implantable vascular devices tailored for vascular surgeons.
LeMaitre (Nasdaq:LMAT) has been added to the NASDAQ US Broad Dividend Achievers Index, recognizing companies with a decade of increasing dividends. Since initiating dividends in 2011, LeMaitre's payout per share rose from $0.08 to $0.44 in 2021, achieving an 18.6% compounded annual growth rate. A new quarterly dividend of $0.125 will be distributed on March 24, 2022. CEO George W. LeMaitre emphasized the company's commitment to profitability and an improved balance sheet through consistent dividend increases.
LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced its participation in four significant investor conferences this March. The 34th Annual Roth Conference is scheduled for March 14, 2022, with President David Roberts presenting. Following that, the Oppenheimer 32nd Annual Healthcare Conference takes place on March 16, 2022, featuring CFO JJ Pellegrino. On March 17, 2022, Roberts will present at the Barclays Global Healthcare Conference, and the month concludes with the KeyBanc Life Sciences & MedTech Investor Forum on March 22, 2022.
LeMaitre (Nasdaq:LMAT) reported Q4 2021 sales of $39.5 million, a 5% increase year-over-year, driven by higher sales of bovine grafts and patches. Operating income fell 13% to $8.3 million, with an operational margin of 21%. The company announced a 14% increase in its quarterly dividend to $0.125 per share, marking the 11th consecutive year of dividend growth. For Q1 2022, guidance suggests sales between $37.7 million and $39.7 million, with a gross margin of 66.2%. Full-year 2022 guidance anticipates sales of $162 million to $166 million, aiming for an EPS of $1.35 to $1.45.
LeMaitre Vascular, Inc. (LMAT) will release its fourth quarter 2021 financial results on February 24, 2022, after market close. A conference call is scheduled for 5:00 PM ET that day to discuss the results and company outlook. The company provides devices and services for peripheral vascular disease, affecting over 200 million people globally. Investors can access the live call by dialing 800-773-2954 or through a webcast on the company's investor relations website.
LeMaitre Vascular announced that CFO JJ Pellegrino will present at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference on February 16, 2022, at 10:30 AM ET. The company specializes in devices and services for treating peripheral vascular disease, impacting over 200 million people globally. LeMaitre develops and markets both disposable and implantable vascular devices tailored for vascular surgeons. More information is available at www.lemaitre.com.
LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced that CFO JJ Pellegrino will present at the 24th Annual Needham Virtual Growth Conference on January 14, 2022, at 3:30 PM. The company specializes in devices and services for treating peripheral vascular disease, which affects over 200 million people globally. LeMaitre develops a range of disposable and implantable vascular devices aimed at meeting the needs of vascular surgeons. Additional details are available on their website at www.lemaitre.com.
LeMaitre Vascular, Inc. (Nasdaq:LMAT) has announced participation in three upcoming virtual investor conferences:
- Stifel 2021 Virtual Healthcare Conference – November 15, 2021, 8:40 AM ET (David Roberts, President)
- Canaccord Genuity Virtual MedTech, Diagnostics and Digital Health & Services Forum – November 18, 2021 (JJ Pellegrino, CFO)
- Piper Sandler 33rd Virtual Annual Healthcare Conference – November 29 – December 2, 2021 (Pre-recorded presentation by David Roberts)
LeMaitre specializes in medical devices for peripheral vascular disease, serving over 200 million affected patients globally.
LeMaitre (Nasdaq:LMAT) reported Q3 2021 sales of $38.4 million, a 5% increase year-over-year, with a gross margin of 64.8%, up 250 basis points. Operating income dropped 9% to $9.1 million, and net income fell 13% to $6.5 million. Earnings per diluted share were $0.30, down 19%. The company announced a quarterly dividend of $0.11 per share. Guidance for Q4 2021 expects sales between $39.0 million and $41.0 million, with a gross margin of 66.3%. CEO George LeMaitre noted challenges from the Delta variant affecting elective surgeries.